References

Citations

1. American Cancer Society (2006). Cancer Facts and Figures 2006, pp. 1–56. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.

2. Kantoff PW (2007). Prostate cancer. In DC Dale, DD Federman, eds., ACP Medicine, section 12, chap. 9. New York: WebMD.

3. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361(9360): 859–864.

4. U.S. Preventive Services Task Force (2003). Screening for prostate cancer: Recommendations and rationale. American Family Physician, 67(4): 787–792.

5. National Institutes of Health (2007). Prostate cancer genetics: Fact sheet. Available online: http://www.nih.gov/about/researchresultsforthepublic.

6. Klein EA, et al. (2007). Epidemiology, etiology, and prevention of prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2854–2873. Philadelphia: Saunders Elsevier.

7. Robbins C, et al. (2007). Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Research, 17(12): 1717–1722.

8. National Cancer Institute (2007). Prostate Cancer (PDQ): Prevention—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional.

9. Bill–Axelson A, et al. (2005). Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 352(19): 1977–1984.

10. Punglia RS, et al. (2003). Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New England Journal of Medicine, 349(4): 335–342.

11. Scher HI, et al. (2005). Cancer of the prostate. In VT DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 1192–1259. Philadelphia: Lippincott Williams and Wilkins.

12. Badani KK, et al. (2007). Evolution of robotic radical prostatectomy: Assessment after 2,766 procedures. Cancer, 110(9): 1951–1958.

13. Brada M, et al. (2007). Proton therapy in clinical practice: Current clinical evidence. Journal of Clinical Oncology, 25(8): 965–970.

14. D'Amico AV, et al. (2007). Radiation therapy for prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 3006–3031. Philadelphia: Saunders Elsevier.

15. Iversen P, et al. (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3–year median followup from the Scandinavian Prostate Cancer Group Study No. 6. Journal of Urology, 172(5, Part 1): 1871–1876.

16. Agency for Healthcare Research and Quality (2008). Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: Executive Summary (AHRQ Pub. No. 08-EHC010-1). Rockville, MD: Agency for Healthcare Research and Quality. Available online: http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9&DocID=79.

Other Works Consulted

• Agency for Healthcare Research and Quality (2008). Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: Executive Summary (AHRQ Pub. No. 08-EHC010-1). Rockville, MD: Agency for Healthcare Research and Quality. Available online: http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9&DocID=79.

• Ahmed HU, et al. (2007). Will focal therapy become a standard of care for men with localized prostate cancer? Nature Clinical Practice Oncology, 4(11): 632–642.

• Chen RC, et al. (2008). Treatment "mismatch" in early prostate cancer: Do treatment choices take patient quality of life into account? Cancer, 112(1): 61–68.

• D’Amico, et al. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA, 299(3): 289–295.

• Elkord E (2007). Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Disease, 10(3): 224–236.

• Hartke DM, Resnick MI (2007). Radical perineal prostatectomy. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2979–2984. Philadelphia: Saunders Elsevier.

• Iversen P, et al. (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study No. 6. Journal of Urology, 172(5, Part 1): 1871–1876.

• National Comprehensive Cancer Network and the American Cancer Society (2007). Clinical Practice Guidelines in Oncology: Prostate Cancer, V.2.2007. Jenkintown, PA: National Comprehensive Cancer Network. Available online: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.

• National Institutes of Health (2007). Prostate cancer genetics: Fact sheet. Available online: http://www.nih.gov/about/researchresultsforthepublic.

• Redman MW, et al. (2008). Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prevention Research. Published online May 18, 2008 (doi:10.1158/1940-6207.CAPR-08-0092).

• Su L, Smith JA (2007). Laparoscopic and robotic-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy. In AJ Wein et al., eds. Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2985–3005. Philadelphia: Saunders Elsevier.

• Tsai HK, et al. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute, 99(20): 1516–1524.

• Tunn U (2007). The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. British Journal of Urology International, 99(Suppl 1): 19–24.